National Pregnancy Registry for Psychiatric Medications©

The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, and atypical antipsychotics that many people take during pregnancy to treat a wide range of mood, anxiety, executive function, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy, as current data is limited.

If you are pregnant and have taken an antidepressant, ADHD medication, or atypical antipsychotic, please click the participation information button above. Individuals with a history of psychiatric illness who are pregnant and have not taken an antidepressant, ADHD medication, or atypical antipsychotic are also welcome to enroll in the Registry.

Cohen, L. S., Church, T. R., Freeman, M. P., Gaccione, P., Caplin, P. S., Kobylski, L. A., Arakelian, M., Rossa, E. T., Chitayat, D., Hernández-Díaz, S., & Viguera, A. C. (2023). Reproductive Safety of Lurasidone and Quetiapine: Update from the National Pregnancy Registry for Psychiatric MedicationsJournal of women’s health (2002)32(4), 452–462.

Viguera, A. C., McElheny, S. A., Caplin, P. S., Kobylski, L. A., Rossa, E. T., Young, A. V., Gaccione, P., Góez-Mogollón, L., Freeman, M. P., & Cohen, L. S. (2023). Risk of Poor Neonatal Adaptation Syndrome Among Infants Exposed to Second-Generation Atypical Antipsychotics Compared to Antidepressants: Results From the National Pregnancy Registry for Psychiatric MedicationsThe Journal of clinical psychiatry84(1), 22m14492.

Freeman, M. P., Szpunar, M. J., Kobylski, L. A., Harmon, H., Viguera, A. C., & Cohen, L. S. (2022). Pregnancy outcomes after first-trimester exposure to buspirone: prospective longitudinal outcomes from the MGH National Pregnancy Registry for Psychiatric MedicationsArchives of women’s mental health25(5), 923–928.

Szpunar, M. J., Freeman, M. P., Kobylski, L. A., Caplin, P. S., Gaccione, P., Viguera, A. C., Chitayat, D., Hernández-Díaz, S., & Cohen, L. S. (2022). Risk of major malformations in infants after first-trimester exposure to benzodiazepines: Results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric MedicationsDepression and anxiety39(12), 751–759.

Viguera, A. C., Vanderkruik, R., Gaccione, P., Caplin, P. S., Kobylski, L. A., Freeman, M. P., & Cohen, L. S. (2022). Breastfeeding practices among women taking second-generation antipsychotics: findings from the National Pregnancy Registry for Atypical AntipsychoticsArchives of women’s mental health25(2), 511–516.

Viguera, A. C., Freeman, M. P., Góez-Mogollón, L., Sosinsky, A. Z., McElheny, S. A., Church, T. R., Young, A. V., Caplin, P. S., Chitayat, D., Hernández-Díaz, S., & Cohen, L. S. (2021). Reproductive Safety of Second-Generation Antipsychotics: Updated Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical AntipsychoticsThe Journal of clinical psychiatry82(4), 20m13745.

Freeman, M. P., Viguera, A. C., Góez-Mogollón, L., Young, A. V., Caplin, P. S., McElheny, S. A., Church, T. R., Chitayat, D., Hernández-Díaz, S., & Cohen, L. S. (2021). Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical AntipsychoticsArchives of women’s mental health24(4), 659–667.

Freeman, M. P., Goez-Mogollon, L., Sosinsky, A. Z., Church, T. R., McElheny, S. A., Viguera, A. C., & Cohen, L. S. (2019). The impact of obesity on pregnancy outcomes among women with psychiatric disorders: Results from a prospective pregnancy registryJournal of psychosomatic research123, 109735.

Freeman, M. P., Sosinsky, A. Z., Goez-Mogollon, L., Savella, G. M., Moustafa, D., Viguera, A. C., & Cohen, L. S. (2018). Gestational Weight Gain and Pre-pregnancy Body Mass Index Associated With Second-Generation Antipsychotic Drug Use During PregnancyPsychosomatics59(2), 125–134.

Cohen, L. S., Góez-Mogollón, L., Sosinsky, A. Z., Savella, G. M., Viguera, A. C., Chitayat, D., Hernández-Díaz, S., & Freeman, M. P. (2018). Risk of Major Malformations in Infants Following First-Trimester Exposure to QuetiapineThe American journal of psychiatry175(12), 1225–1231.

Freeman, M. P., Farchione, T., Yao, L., Sahin, L., Taylor, L., Huybrechts, K. F., Nonacs, R., Sosinsky, A. Z., Viguera, A. C., & Cohen, L. S. (2018). Psychiatric Medications and Reproductive Safety: Scientific and Clinical Perspectives Pertaining to the US FDA Pregnancy and Lactation Labeling RuleThe Journal of clinical psychiatry79(4), 18ah38120.

Freeman, M. P., Góez-Mogollón, L., McInerney, K. A., Davies, A. C., Church, T. R., Sosinsky, A. Z., Noe, O. B., Viguera, A. C., & Cohen, L. S. (2018). Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: Results from a prospective registry of women with psychiatric disordersGeneral hospital psychiatry53, 73–79.

Park, Y., Hernandez-Diaz, S., Bateman, B. T., Cohen, J. M., Desai, R. J., Patorno, E., Glynn, R. J., Cohen, L. S., Mogun, H., & Huybrechts, K. F. (2018). Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational DiabetesThe American journal of psychiatry175(6), 564–574.

Freeman, M. P., Sosinsky, A. Z., Goez-Mogollon, L., Savella, G. M., Moustafa, D., Viguera, A. C., & Cohen, L. S. (2018). Gestational Weight Gain and Pre-pregnancy Body Mass Index Associated With Second-Generation Antipsychotic Drug Use During PregnancyPsychosomatics59(2), 125–134.

Panchaud, A., Hernandez-Diaz, S., Freeman, M. P., Viguera, A. C., MacDonald, S. C., Sosinsky, A. Z., & Cohen, L. S. (2017). Use of atypical antipsychotics in pregnancy and maternal gestational diabetesJournal of psychiatric research95, 84–90.

Sosinsky, A. Z., Freeman, M. P., Savella, G. M., Cheng, L. J., Viguera, A. C., & Cohen, L. S. (2017). Delusional Pregnancy Presenting to the Massachusetts General Hospital National Pregnancy Registry for Atypical AntipsychoticsJournal of clinical psychopharmacology37(4), 472–474.

Patorno, E., Huybrechts, K. F., Bateman, B. T., Cohen, J. M., Desai, R. J., Mogun, H., Cohen, L. S., & Hernandez-Diaz, S. (2017). Lithium Use in Pregnancy and the Risk of Cardiac MalformationsThe New England journal of medicine376(23), 2245–2254.

Huybrechts, K. F., Hernández-Díaz, S., Patorno, E., Desai, R. J., Mogun, H., Dejene, S. Z., Cohen, J. M., Panchaud, A., Cohen, L., & Bateman, B. T. (2016). Antipsychotic Use in Pregnancy and the Risk for Congenital MalformationsJAMA psychiatry73(9), 938–946.

Freeman, M. P., Sosinsky, A. Z., Moustafa, D., Viguera, A. C., & Cohen, L. S. (2016). Supplement use by women during pregnancy: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical AntipsychoticsArchives of women’s mental health19(3), 437–441.

Cohen, L. S., Viguera, A. C., McInerney, K. A., Freeman, M. P., Sosinsky, A. Z., Moustafa, D., Marfurt, S. P., Kwiatkowski, M. A., Murphy, S. K., Farrell, A. M., Chitayat, D., & Hernández-Díaz, S. (2016). Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical AntipsychoticsThe American journal of psychiatry173(3), 263–270.

Cohen, L. S., Viguera, A. C., McInerney, K. A., Freeman, M. P., Sosinsky, A. Z., Moustafa, D., Marfurt, S. P., Kwiatkowski, M. A., Murphy, S. K., Farrell, A. M., Chitayat, D., & Hernández-Díaz, S. (2016). Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical AntipsychoticsThe American journal of psychiatry173(3), 263–270.

Cohen, L. S., Viguera, A. C., McInerney, K. A., Kwiatkowski, M. A., Murphy, S. K., Lemon, E. L., & Hernández-Díaz, S. (2015). Establishment of the National Pregnancy Registry for Atypical AntipsychoticsThe Journal of clinical psychiatry76(7), 986–989.

Freeman, M. P. (2015). Psychotropic medication use during pregnancy: changes to the labeling system and the importance of exposure registriesThe Journal of clinical psychiatry76(7), 990–991.

Huybrechts, K. F., Palmsten, K., Avorn, J., Cohen, L. S., Holmes, L. B., Franklin, J. M., Mogun, H., Levin, R., Kowal, M., Setoguchi, S., & Hernández-Díaz, S. (2014). Antidepressant use in pregnancy and the risk of cardiac defectsThe New England journal of medicine370(25), 2397–2407.

Required Sponsorship Disclosures:

Current Sponsors: Alkermes, Inc. (2016-Present); Dr. Reddy’s Laboratories, Inc. (2023-Present); Eisai Inc. (2022 – Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Supernus Pharmaceuticals (2021-Present); Teva Pharmaceutical Industries Ltd. (2018-Present).

Past Sponsors: Forest/Actavis/Allergan (2016-2018, declined to sponsor: 2018-Present); Aurobindo Pharma (2020-2022, declined to sponsor: 2022-Present); AstraZeneca Pharmaceuticals (2009-2014, declined to sponsor: 2014-Present); AuroMedics Pharma LLC (2021-2022, declined to sponsor: 2022-Present); Johnson & Johnson/Janssen Pharmaceuticals, Inc (2019-2023, declined to sponsor: 2024-Present) ; Ortho-McNeil-Janssen Pharmaceuticals, Inc (2009-2014, declined to sponsor: 2015-Present); Pfizer, Inc. (2009-2011, declined to sponsor: 2012-Present); Sage Therapeutics (2019-2023, declined to sponsor 2024-present); Sunovion Pharmaceuticals, Inc. (2011-2023, declined to sponsor: 2024-Present).

Declined to sponsor: AbbVie Inc.; Ajanta Pharma USA Inc.; Apotex Inc.; Arcolab Private Limited; Eli Lilly and Company; Intra-Cellular Therapies, Inc.; Novartis Pharmaceuticals; Qilu Pharmaceutical Co., Ltd.; Vanda Pharmaceuticals Inc.

Funding Information: Manufacturers of psychiatric medications have been approached regarding funding of the National Pregnancy Registry. Regardless of which entities have supported this initiative, all medications in this class are studied. For more information on how to sponsor the Registry, please see the contact information below.